Opexa offering cuts stock in half to fund MS immunotherapy
This article was originally published in Scrip
Executive Summary
Opexa Therapeutics priced 12 million shares after the market closed on 7 August at $1.50 per share – nearly half of the company's $2.92 closing price – to raise $18 million for its ongoing Phase IIb clinical trial for the personalized multiple sclerosis immunotherapy Tcelna.